Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Immunol. 2013 May;33(4):876-9. doi: 10.1007/s10875-012-9857-y. Epub 2013 Jan 29.

Decreased levels of circulating CD4+CD25+Foxp3+ regulatory T cells in patients with primary antiphospholipid syndrome.

Author information

1
Laboratory of Immunosenescence, Institute of Biomedical Research, Faculty of Biosciences, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil.

Abstract

INTRODUCTION:

CD4(+)CD25(+)Foxp3(+) regulatory T (Treg) cell dysfunction has been documented in various autoimmune disorders, but not in antiphospholipid syndrome (APS) so far.

METHODS:

In this cross-sectional study, we aim to investigate CD4(+)CD25(+)Foxp3(+) Treg cells, CD3(+)CD19(-) T cells and CD3(-)CD19(+) B cells in patients with primary APS and healthy controls. Cell subtypes were immunophenotyped using specific monoclonal antibodies (anti-CD3 CY5, anti-CD4 FITC, anti-CD25, anti-Foxp3, anti-CD19 PE) and flow cytometry.

RESULTS:

Twenty patients with APS and 20 age- and sex-matched controls were studied. The percentage of total lymphocytes, activated Th cells (CD4+CD25+), Treg cells and CD3(-)CD19(+) B cells were found significantly lower in APS patients as compared to controls (all pā€‰<ā€‰0.05).

CONCLUSION:

A dysfunction in CD4(+)CD25(+)Foxp3(+) Treg cells may represent one of the mechanisms leading to autoimmunity in APS patients. The decreased number of CD3(-)CD19(+) B cells of APS patients warrants further elucidation.

PMID:
23354908
DOI:
10.1007/s10875-012-9857-y
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center